Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

19.15 +1.16 (+6.45%)
Streaming Delayed Price Updated: 3:03 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 438,722
Open 18.40
Bid (Size) 19.12 (2)
Ask (Size) 19.14 (1)
Prev. Close 17.99
Today's Range 18.15 - 19.24
52wk Range 10.87 - 41.51
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down NovoCure: 4 Analysts Share Their Views
Via Benzinga
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire

Performance

YTD
+32.99%
+32.99%
1 Month
-1.29%
-1.29%
3 Month
+50.55%
+50.55%
6 Month
+52.10%
+52.10%
1 Year
-52.80%
-52.80%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
A Closer Look at 7 Analyst Recommendations For NovoCure
Via Benzinga
Unveiling 8 Analyst Insights On NovoCure
Via Benzinga
Why NovoCure Stock Soared 18.3% This Week
Via The Motley Fool
Why Novocure Stock Is Jumping Today
Via The Motley Fool
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
From Novocure
Via Business Wire
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
Via Benzinga
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
Via InvestorPlace
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
From Novocure
Via Business Wire
Novocure Reports First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.